Lunit Inc. and Summit Therapeutics have entered a research agreement to use Lunit's AI-powered pathology platform, Lunit SCOPE IO, for analyzing tumor microenvironments in support of Summit's immuno-oncology drug ivonescimab. The AI platform will analyze standard H&E-stained tissue slides to identify tumor features that could help discover biomarkers and improve patient selection for therapies. This collaboration aims to enhance understanding of tumor biology and support the development of ivonescimab, a novel bispecific antibody targeting PD-1 and VEGF, currently in multiple Phase III trials. The research highlights the growing role of AI in oncology drug development by enabling scalable, detailed analysis of tumor tissues.
Summit Therapeutics shares are priced at USD 15.47 on Pluang as of Oct 24, 2026 08:41 WIB. The stock has experienced a slight decline of 0.51% in the past day. Investors typically hold Summit shares for about 17 days on the platform.
